Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prazosin for Alcohol Use Disorder With Alcohol Withdrawal Symptoms
NCT04793685Phase 2Completed
- Sponsor
- Yale University
- Start
- Jul 2021
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in alcohol use disorder (AUD) and alcohol withdrawal syndrome (AWS) comparing Active Drug (Prazosin) with Placebo Drug (2 arms). Primary endpoint: Percent Heavy Drinking Days. Started Jul 2021; status: completed.
02
Drugs
prazosin
03
Conditions
alcohol use disorder (AUD)alcohol withdrawal syndrome (AWS)
Beyond the preview
Go deeper on NCT04793685.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04793685.